233 related articles for article (PubMed ID: 36725090)
1. Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of a pilot study.
Verburgt CM; Dunn KA; Otley A; Heyman MB; Verstraete S; Sunseri W; Sylvester F; de Meij T; Comeau A; Langille M; de Jonge WJ; Benninga MA; Van Limbergen JE
BMJ Open; 2023 Feb; 13(2):e064944. PubMed ID: 36725090
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial.
Levine A; Kori M; Kierkus J; Sigall Boneh R; Sladek M; Escher JC; Wine E; Yerushalmi B; Amil Dias J; Shaoul R; Veereman Wauters G; Boaz M; Abitbol G; Bousvaros A; Turner D
Gut; 2019 Feb; 68(2):239-247. PubMed ID: 29420227
[TBL] [Abstract][Full Text] [Related]
3. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
Yanai H; Levine A; Hirsch A; Boneh RS; Kopylov U; Eran HB; Cohen NA; Ron Y; Goren I; Leibovitzh H; Wardi J; Zittan E; Ziv-Baran T; Abramas L; Fliss-Isakov N; Raykhel B; Gik TP; Dotan I; Maharshak N
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):49-59. PubMed ID: 34739863
[TBL] [Abstract][Full Text] [Related]
4. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial.
Levine A; Wine E; Assa A; Sigall Boneh R; Shaoul R; Kori M; Cohen S; Peleg S; Shamaly H; On A; Millman P; Abramas L; Ziv-Baran T; Grant S; Abitbol G; Dunn KA; Bielawski JP; Van Limbergen J
Gastroenterology; 2019 Aug; 157(2):440-450.e8. PubMed ID: 31170412
[TBL] [Abstract][Full Text] [Related]
5. Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn's Disease Cohort.
Sprockett D; Fischer N; Boneh RS; Turner D; Kierkus J; Sladek M; Escher JC; Wine E; Yerushalmi B; Dias JA; Shaoul R; Kori M; Snapper SB; Holmes S; Bousvaros A; Levine A; Relman DA
Inflamm Bowel Dis; 2019 Nov; 25(12):1927-1938. PubMed ID: 31276165
[TBL] [Abstract][Full Text] [Related]
6. Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA.
Minar PP; Colman RJ; Zhang N; Mizuno T; Vinks AA
BMJ Open; 2024 Mar; 14(3):e077193. PubMed ID: 38531570
[TBL] [Abstract][Full Text] [Related]
7. Formula modifications to the Crohn's disease exclusion diet do not impact therapy success in paediatric Crohn's disease.
Landorf E; Hammond P; Abu-Assi R; Ellison S; Boyle T; Comerford A; Couper R
J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1279-1286. PubMed ID: 38623960
[TBL] [Abstract][Full Text] [Related]
8. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease.
Levine A; Turner D
J Crohns Colitis; 2011 Jun; 5(3):222-6. PubMed ID: 21575885
[TBL] [Abstract][Full Text] [Related]
9. Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn's disease population: PediCRaFT Trial.
Pai N; Popov J; Hill L; Hartung E
BMJ Open; 2019 Nov; 9(11):e030120. PubMed ID: 31784432
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Crohn's disease exclusion diet in treatment -naïve children and children progressed on biological therapy: a retrospective chart review.
Jijón Andrade MC; Pujol Muncunill G; Lozano Ruf A; Álvarez Carnero L; Vila Miravet V; García Arenas D; Egea Castillo N; Martín de Carpi J
BMC Gastroenterol; 2023 Jun; 23(1):225. PubMed ID: 37386458
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics for induction and maintenance of remission in Crohn's disease.
Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Active Crohn's Disease in Children Using Partial Enteral Nutrition Combined with a Modified Crohn's Disease Exclusion Diet: A Pilot Prospective Cohort Trial on Clinical and Endoscopic Outcomes.
Urlep D; Orel R; Kunstek P; Benedik E
Nutrients; 2023 Nov; 15(21):. PubMed ID: 37960328
[TBL] [Abstract][Full Text] [Related]
13. Sustained Diet-Induced Remission in Pediatric Crohn's Disease Is Associated With Kynurenine and Serotonin Pathways.
Ghiboub M; Boneh RS; Sovran B; Wine E; Lefèvre A; Emond P; Verburgt CM; Benninga MA; de Jonge WJ; Van Limbergen JE
Inflamm Bowel Dis; 2023 May; 29(5):684-694. PubMed ID: 36637175
[TBL] [Abstract][Full Text] [Related]
14. Effect of the Crohn's Disease Exclusion Diet (CDED) on the Fecal Calprotectin Level in Children with Active Crohn's Disease.
Matuszczyk M; Meglicka M; Wiernicka A; Jarzębicka D; Osiecki M; Kotkowicz-Szczur M; Kierkuś J
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887910
[TBL] [Abstract][Full Text] [Related]
15. Metabolome Changes With Diet-Induced Remission in Pediatric Crohn's Disease.
Ghiboub M; Penny S; Verburgt CM; Boneh RS; Wine E; Cohen A; Dunn KA; Pinto DM; Benninga MA; de Jonge WJ; Levine A; Van Limbergen JE
Gastroenterology; 2022 Oct; 163(4):922-936.e15. PubMed ID: 35679949
[TBL] [Abstract][Full Text] [Related]
16. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
[TBL] [Abstract][Full Text] [Related]
17. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
18. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
19. Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial.
Janssen L; Romberg-Camps M; van Bodegraven A; Haans J; Aquarius M; Boekema P; Munnecom T; Brandts L; Joore M; Masclee A; Jonkers D; Pierik M
BMJ Open; 2021 May; 11(5):e042885. PubMed ID: 33947729
[TBL] [Abstract][Full Text] [Related]
20. Effects of ileocolonic delivered vitamin B
Otten AT; Peters V; Barth I; Stevens CL; Bourgonje AR; Frijlink HW; Harmsen HJM; Rehman A; Campmans-Kuijpers MJE; Dijkstra G
BMJ Open; 2023 Mar; 13(3):e069654. PubMed ID: 36918234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
